Literature DB >> 14988160

Telomere length correlates with histopathogenesis according to the germinal center in mature B-cell lymphoproliferative disorders.

Marco Ladetto1, Mara Compagno, Irene Ricca, Marco Pagano, Alberto Rocci, Monica Astolfi, Daniela Drandi, Paola Francia di Celle, Maria Dell'Aquila, Barbara Mantoan, Sonia Vallet, Gloria Pagliano, Federica De Marco, Roberto Francese, Loredana Santo, Alessandra Cuttica, Carlo Marinone, Mario Boccadoro, Corrado Tarella.   

Abstract

In this study we investigated telomere restriction fragment (TRF) length in a panel of mature B-cell lymphoproliferative disorders (MBCLDs) and correlated this parameter with histology and histopathogenesis in relation to the germinal center (GC). We assessed 123 MBCLD samples containing 80% or more tumor cells. TRF length was evaluated by Southern blot analysis using a chemiluminescence-based assay. GC status was assessed through screening for stable and ongoing somatic mutations within the immunoglobulin heavy-chain genes. Median TRF length was 6170 bp (range, 1896-11 200 bp) and did not correlate with patient age or sex. TRF length was greater in diffuse large cell lymphoma, Burkitt lymphoma, and follicular lymphoma (medians: 7789 bp, 9471 bp, and 7383 bp, respectively) than in mantle cell lymphoma and chronic lymphocytic leukemia (medians: 3582 bp and 4346 bp, respectively). GC-derived MBCLDs had the longest telomeres, whereas those arising from GC-inexperienced cells had the shortest (P < 10(-9)). We conclude that (1) TRF length in MBCLD is highly heterogeneous; (2) GC-derived tumors have long telomeres, suggesting that minimal telomere erosion occurs during GC-derived lymphomagenesis; and (3) the short TRF lengths of GC-inexperienced MBCLDs indicates that these neoplasms are good candidates for treatment with telomerase inhibitors, a class of molecules currently the subject of extensive preclinical evaluation.

Entities:  

Mesh:

Year:  2004        PMID: 14988160     DOI: 10.1182/blood-2003-12-4412

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Altered mRNA expression of telomere-associated genes in monoclonal gammopathy of undetermined significance and multiple myeloma.

Authors:  Julieta Panero; Jorge Arbelbide; Dorotea Beatriz Fantl; Hernán García Rivello; Dana Kohan; Irma Slavutsky
Journal:  Mol Med       Date:  2010-07-14       Impact factor: 6.354

Review 2.  The biology of aging and lymphoma: a complex interplay.

Authors:  Clémentine Sarkozy; Gilles Salles; Claire Falandry
Journal:  Curr Oncol Rep       Date:  2015-07       Impact factor: 5.075

Review 3.  Novel therapeutics for aggressive non-Hodgkin's lymphoma.

Authors:  Daruka Mahadevan; Richard I Fisher
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

4.  Impact of telomere length on survival in classic and variant hairy cell leukemia.

Authors:  Evgeny Arons; Hong Zhou; Daniel C Edelman; Allison Gomez; Seth M Steinberg; David Petersen; Yonghong Wang; Paul S Meltzer; Robert J Kreitman
Journal:  Leuk Res       Date:  2015-09-24       Impact factor: 3.156

5.  High-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission.

Authors:  Ignazio Majolino; Marco Ladetto; Anna Locasciulli; Daniela Drandi; Fabio Benedetti; Andrea Gallamini; Teodoro Chisesi; Angelo De Blasio; Mario Boccadoro; Corrado Tarella
Journal:  Med Oncol       Date:  2006       Impact factor: 3.738

Review 6.  Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance.

Authors:  Michele Dal-Bo; Francesco Bertoni; Francesco Forconi; Antonella Zucchetto; Riccardo Bomben; Roberto Marasca; Silvia Deaglio; Luca Laurenti; Dimitar G Efremov; Gianluca Gaidano; Giovanni Del Poeta; Valter Gattei
Journal:  J Transl Med       Date:  2009-08-28       Impact factor: 5.531

7.  Telomere Length, TERT, and miRNA Expression.

Authors:  Martha L Slattery; Jennifer S Herrick; Andrew J Pellatt; Roger K Wolff; Lila E Mullany
Journal:  PLoS One       Date:  2016-09-14       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.